Genmab falls on zalutumumab data

Genmab A/S (CSE:GEN) fell DKK18.85 (20%) to DKK73.50 on Monday after zalutumumab plus best supportive care missed the primary endpoint of significantly increasing median overall survival vs. best supportive care alone in a Phase III trial to treat squamous cell carcinoma of the head and neck (SSCHN) in patients refractory to standard platinum-based chemotherapy (6.7 vs. 5.2 months, p=0.0648). The human mAb targeting EGFR did significantly increase progression-free survival (PFS) by 61% vs. best supportive care alone (p=0.001). ...